Title |
A proposed preventive role for Gamma-hydroxybutyrate (XyremR) in Alzheimer’s disease
|
---|---|
Published in |
Alzheimer's Research & Therapy, September 2016
|
DOI | 10.1186/s13195-016-0205-y |
Pubmed ID | |
Authors |
Michel Maitre, Christian Klein, Ayikoe G. Mensah-Nyagan |
Abstract |
Gamma-hydroxybutyrate (GHB or Xyrem(R)) is frequently used in humans for several clinical indications, including anesthesia, narcolepsy/cataplexy, and alcohol-withdrawal symptoms. Pharmacological effects induced in the brain by therapeutic doses of Xyrem(R) are generally GABAergic-dependent. These effects allow sedation, stress/anxiety reduction, deep sleep induction, decrease of neuroinflammation, and neuroprotection. Furthermore, Xyrem(R) promotes the expression of pivotal genes reducing toxic proteinopathies, as demonstrated in laboratory animal models. Altogether, these data represent additional evidence to suggest that Xyrem(R) may be tested during repeated short periods in populations at risk for Alzheimer's disease. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Bolivia, Plurinational State of | 1 | 17% |
United Kingdom | 1 | 17% |
Australia | 1 | 17% |
United States | 1 | 17% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 48 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 19% |
Student > Bachelor | 6 | 13% |
Student > Ph. D. Student | 6 | 13% |
Student > Postgraduate | 3 | 6% |
Researcher | 3 | 6% |
Other | 5 | 10% |
Unknown | 16 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Psychology | 7 | 15% |
Medicine and Dentistry | 6 | 13% |
Biochemistry, Genetics and Molecular Biology | 4 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
Nursing and Health Professions | 3 | 6% |
Other | 8 | 17% |
Unknown | 17 | 35% |